All News

RheumNow Podcast square

UBER Rheumatology Ride (3.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Read Article
RheumNow Podcast square

SATISFACTION (2.27.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Merola RNL26 Shot

Paradoxical Reactions, Target Selection & the Future of Imaging in Psoriatic Care

Audrey Gibson, PA-C

From paradoxical psoriasis to IL-23 vs IL-17 to imaging in PsA, speakers in RheumNow Live's "Decisions in Psoriatic Arthritis" pod delivered valuable, clinically relevant education.

Read Article
RheumNow Podcast square

ANA Pollution (2.06.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com

Read Article
2025

The 2025 Rheumatology Year in Review

Jack Cush, MD

The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.

Read Article
PSO.Palmoplantar.jpg

Advanced Practitioner Biologic Prescriptions for Psoriasis

Jack Cush, MD

Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA Dermatology reports APC drug spending trends in dermatology, with a focus on specialty medications (eg, biologics).

Read Article
psA.fil_.Hands_.jpg

APEX Study: Inhibition of structural damage progression with Guselkumab in Psoriatic Arthritis

Jack Cush, MD

Guselkumab, a human IL-23 inhibitor, was evaluated in patients with active psoriatic arthritis (PsA) and shown to have both clinical and radiographic benefits at weeks 24 and 48.

Read Article
Cush and Kavanaugh

ACR 2025 Rheumatology Round Up

Jack Cush, MD

Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.

Read Article
acr_session2.jpeg

ACR25 Best Abstracts - Day 4

Jack Cush, MD

Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty.  Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!

Read Article
psoriasis,arms,pain

IL-23 Blockade Goes Oral

Aurelie Najm, MD, PhD

A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.

Read Article
RheumNow Podcast square

Eating Crow (10.10.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.

Read Article
IL-23i fails in GCA? Small RCT of 53 GCA pts (age 71 yrs; 60% new; 40% relapsing GCA) 35 given Guselkumab vs 18 on PBO. Wk 28 GC free remission in 40% vs 33% (P .64), also w/ similar flare rates (31% v 39%). results didnt supportguselkumab use in GCA. https://t.co/AMTmiDBc94 https://t.co/KdWTX9K2Bo

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @gibson_RheumPAC Axial PsA remains an area of active investigation. IL-17 inhibitors show consistent benefit, while IL-23 data are emerging—highlighting nuances when axial symptoms drive treatment choice. #RNL26 https://t.co/XFL3Sf8iK4
Dr. John Cush RheumNow ( View Tweet)
APEX Study: Inhibition of structural damage progression with Guselkumab in PsA Guselkumab, a human IL-23 inhibitor, was evaluated in patients with active PsA and shown to have both clinical and radiographic benefits at weeks 24 and 48. https://t.co/iNEziysnVZ https://t.co/XgFGFfGf3b

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the IL-23R, is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies. https://t.co/fYXULrMD16
Dr. John Cush RheumNow ( View Tweet)
IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and https://t.co/7awBk16ZrQ
Dr. John Cush RheumNow ( View Tweet)
What's the latest in PsA? https://t.co/I8ZgRQpVy6 Great review for whats new in PsA by @drpnash Looking forward for Large IL23-Axial study results. @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

Heydari-Kamjani et al. TriNetX study. 28973 PsA patients. IL-17i and IL-23i lower rates stroke, MI, DVT/PE than TNFi. IL-12/23i higher rate of stroke vs TNFi. @RheumNow #ACR25 Abstr#2363 https://t.co/fNHaxyYPCP

Links:

Richard Conway RichardPAConway ( View Tweet)
Icotrokinra, the new kid on the bloc! Targeted oral peptide IL-23R-inhibitor Effective in Ph2 and Ph3 in PSO Adults Data in Adolescents (12-18yo) with PSO ICO 200mg QD 44pts vs. PBO 22pts 16wks All pts received ICO wk16-wk24 Clear/Almost clear skin IGA 0/1 84% vs. 24% PASI 90 https://t.co/77YvXtdLi1

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts IL-23i and IL-17Ai associated w/ -lower risks of diabetes -Diabetic nephropathy -Stage 3–5 CKD and reduced risk compared to TNFi treated and bionaive pts Adjustment on several variables, but not disease severity https://t.co/TDIHXJOC2T

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×